Nonetheless, other data suggest that the implications of these effects for tumor immunity should be made with caution, as a recent study by Aston et al., demonstrated that, while Dex treatment of mesothelioma-bearing mice resulted in significant decreases in peripheral blood CD4+, CD8+ T cells, T-regs, B cells, and NK cells, the tumor infiltration by these immune subsets was not affected. Here, CD8A is linked to neoplasm.